Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Aldeyra Therapeutics

ChromaDex

Chevron

Home Depot

Intel

Merck

Nuveen Quality Municipal Income Fund

Verizon

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Momenta Pharmaceuticals

Johnson & Johnson to enroll 60,000 participants in the late-stage trial for its COVID-19 vaccine.

Johnson & Johnson to acquire Momenta Pharmaceuticals for $6.5 billion

Medtronic

Procter & Gamble

These companies issue steady dividends and then increase them over time like clockwork.

4 Dividend Stocks That Are Perfect for Retirement

Cisco Systems

Coca-Cola

McDonald's

NIKE

Visa

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

With an upcoming election and ongoing fiscal stimulus concerns, it is time to get defensive. Here are seven safe stocks to buy now.

7 Safe Stocks to Buy That Can Shrug Off the Growing Volatility

Johnson & Johnson (NYSE: JNJ) plans on enrolling up to 60,000 people in a coronavirus vaccine trial, likely as part of a global development and regulatory approval strategy, ex-FDA Commissioner Scott Gottlieb said Friday on CNBC's "Squawk Box.

Ex-FDA Commissioner Analyzes Johnson & Johnson's Mega Vaccine Trial

Johnson & Johnson (NYSE: JNJ) is borrowing $7.5 billion in bonds to help fund its purchase of Momenta Pharmaceuticals, Inc (NASDAQ: MNTA) as a series of companies tap the debt market to finance merger and acquisitions, Bloomberg reported Thursday.

Johnson & Johnson Borrows $7.5B To Fund Its Purchase Of Momenta

Approval broadens DARZALEX label to include fifth treatment option in the relapsed/refractory setting and represents the eighth approved indication for DARZALEX

U.S. FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma

The company aims to recruit 60,000 participants for the study.

Johnson & Johnson to Launch Late-Stage Coronavirus Vaccine Trials in September

A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.

ETFs in Focus on Momenta Buyout Deal With JNJ

Johnson & Johnson plans to begin what would be the largest, late-stage trial testing a potential coronavirus vaccine in September, the company confirmed Thursday.

Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

MOMENTA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Momenta Pharmaceuticals, Inc. - MNTA

AstraZeneca

BioNTech SE

Moderna

Pfizer

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

This 5-Stock Portfolio Is A Safe Bet On A Future COVID-19 Vaccine

J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.

J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence

Momenta (MNTA) soars on the announcement of being acquired by Johnson & Johnson for $6.5 billion.

Momenta Surges on Acquisition Deal With Johnson & Johnson

NEW BRUNSWICK, N.J., Aug. 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Lewis Cantley, Ph.D.

Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative

The stock price of Momenta Pharmaceuticals, a pharmaceutical company best known for its immunology therapies, has rallied around 26% over recent weeks (vs. about a 50% gain in the S&P 500) to $31 as of August 18, after falling to a low of $24 in late March, when a rapid increase in the number.

Is Momenta A Good Fit For JNJ?

Momenta Pharmaceuticals (MNTA) news for Wednesday includes a deal with Johnson & Johnson (JNJ) sending MNTA stock rocketing higher.

Momenta Pharmaceuticals News: MNTA Stock Rockets 69% on JNJ Deal

A healthcare titan is acquiring the biotech in a $6.5 billion deal.

Why Momenta Pharmaceuticals Stock Rocketed 69% Higher Today

The company is paying a big premium to expand its autoimmune disease treatment footprint.

Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5 Billion in Cash

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc.

MOMENTA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MNTA and Encourages Investors to Contact the Firm

After Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) announced that it would be acquired by pharmaceutical giant Johnson & Johnson (NYSE: JNJ), the biotechnology company’s shares soared on Wednesday.

Johnson & Johnson’s Newest Multibillion Dollar Acquisition

Johnson & Johnson (NYSE: JNJ) and Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced Wednesday a definitive agreement for Johnson & Johnson to acquire for $52.50 per share in cash.

Johnson & Johnson's $6.5B Deal To Buy Momenta: What You Should Know

Johnson & Johnson will buy Momenta Pharmaceuticals for $6.5 billion to broaden its reach in treating autoimmune and rare diseases.
The post Johnson & Johnson To Acquire Momenta Pharmaceuticals For $6.5 Billion appeared first on Investor's Business Daily.

Johnson & Johnson  To Acquire Momenta Pharmaceuticals For $6.5 Billion

Shares of Momenta Pharmaceuticals Inc. MNTA, +5.04% rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by Johnson & Johnson JNJ, +0.73% in a deal valued at $6.5 billion.

Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

News for Johnson & Johnson Stock (JNJ)